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Abstract. In angiogenesis associated with tissue repair 
and disease, fibrin and inflammatory  mediators are of- 
ten involved. We have used three-dimensional fibrin 
matrices to investigate the humoral requirements of hu- 
man microvascular endothelial cells (hMVEC) to form 
capillary-like tubular structures, bFGF and VEGF165 
were unable to induce tubular structures by themselves. 
Simultaneous addition of one or both of these factors 
with TNFet induced outgrowth of tubules, the effect be- 
ing the strongest when bFGF, VEGF165, and TNFa 
were added simultaneously. Exogenously added u-PA, 
but not its nonproteolytic amino-terminal fragment, 
could replace TNFot, suggesting that TNFet-induced 
u-PA synthesis was involved. Soluble u-PA receptor 
(u-PAR) or antibodies that inhibited u-PA activity pre- 
vented the formation of tubular structures by 59-99%. 
e-ACA and trasylol which inhibit the formation and 
activity of plasmin reduced the extent of tube forma- 
tion by 71-95%. TNFoL  or u-PA did not induce tubular 
structures without additional growth factors, bFGF and 
VEGF165 enhanced of the u-PAR by 72 and 46%, but 
TNFot itself also increased u-PAR in hMVEC by 30%. 
Induction of mitogenesis was not the major contribu- 
tion of bFGF and VEGF165 because the cell number did 
not change significantly  in the presence of TNFa, and 
tyrphostin A47, which inhibited mitosis completely, re- 
duced the formation of tubular structures only by 28- 
36%. These data show that induction of cell-bound u-PA 
activity by the cytokine TNFet is required in addition to 
the angiogenic factors VEGF165 and/or bFGF to induce 
in vitro formation of capillary-like structures by hMVEC 
in fibrin matrices. These data may provide insight in the 
mechanism of angiogenesis as occurs in pathological 
conditions. 
GIOGENESIS, the  formation of new  blood  vessels 
from existing ones, plays an important role in the 
development and progression of various patholog- 
ical processes, such as tumor development and rheumatoid 
arthritis (Folkman and Klagsbrun, 1987; Liotta et al., 1991; 
Folkman and Shing, 1992; Montesano, 1992; Colville-Nash 
and Scott,  1992). Fibrin (Dvorak et al., 1992), inflamma- 
tory cells (Polverini, 1989), and angiogenic factors (Broad- 
ley et al., 1989; Klagsburn and D'Amore, 1991; Shweiki et 
al., 1992; Plate et al., 1992; Senger et al., 1993; Koch et al., 
1994) are commonly observed in angiogenesis  associated 
with disease in man. A series of sequential events can be 
distinguished during the formation of new microvessels: 
(a) degradation of the vascular basement membrane and 
the fibrin or interstitial matrix by endothelial cells; (b) en- 
dothelial cell migration;  (c) endothelial proliferation; and 
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(d) the formation of new capillary tubes and a new base- 
ment membrane (Folkman, 1986). 
It is generally assumed that urokinase-type plasminogen 
activator (u-PA) 1  and its inhibitor, the plasminogen activa- 
tor inhibitor I (PAl-l), are involved  in the regulation of 
the first steps of angiogenesis, i.e., local proteolytic remod- 
eling of matrix proteins and migration of endothelial cells 
(Pepper et al., 1987; Bacharach et al., 1992; Niedbala et al., 
1992; van Hinsbergh, 1992; Vassalli, 1994). u-PA converts 
plasminogen into the broadly acting serine protease plas- 
1.  Abbreviations  used  in  this paper:  ATF,  amino-terminal fragment of 
u-PA; bFGF, basic fibroblast growth factor; ~-ACA, e-aminocaproic acid; 
hMVEC, human microvascular endothelial cells; HUVEC, human umbilical 
vein endothelial cells; 125I-DIP-u-PA,  1251-labeled diisopropylfluorophos- 
phate-treated u-PA;  MMP,  matrix metalloproteinase; NBCS,  newborn 
calf serum; PBS-T, PBS supplemented with 0.02%  (vol/vol) Tween 20; 
PAl-l, plasminogen activator inhibitor I; t-PA, tissue-type plasminogen 
activator; TNFa, tumor necrosis factor-a; u-PA, urokinase-type plasmino- 
gen activator; scu-PA, single-chain urokinase-type plasminogen activator; 
u-PAR, cellular receptor for u-PA; VEGF165, 165-kD vascular endothelial 
cell growth factor. 
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matrix proteins, and to activate several matrix metallopro- 
teinases (MMPs), in particular stromelysin-1 (MMP-3), in- 
terstitial collagenase (MMP-1), and gelatinase-B (MMP-9) 
(Woessner, 1991; Docherty et al.,  1992; Matrisian, 1992; 
Nagase, 1994). In human endothelial cells the synthesis of 
u-PA and several of these matrix metalloproteinases is en- 
hanced  by the  inflammatory mediators,  tumor  necrosis 
factor-tx (TNFct) and interleukin-1 (van Hinsbergh et al., 
1990; Hanemaaijer et al., 1993). The activity of u-PA is lo- 
calized by a specific cellular receptor (u-PAR) to the cell 
surface (Blasi et al., 1994; Dan0 et al., 1994). The inactive 
single chain form of u-PA binds  to u-PAR  and is  con- 
verted into its active form. In the cell environment active 
two-chain u-PA is immediately inhibited by PAI-1  (Losk- 
utoff, 1991). The u-PAR enhances this activation and may 
temporarily protect u-PA activity (Ellis et al., 1991), and 
provides the cell with the ability to degrade extracellular 
matrix proteins in a controlled manner (Quax et al., 1991). 
In endothelial cells the u-PAR expression is enhanced by 
the angiogenic factors bFGF (Mignatti et al.,  1991)  and 
VEGF (Pepper et al., 1992)  and by activation of protein 
kinase C and elevation of cyclic AMP concentration (Bar- 
nathan et al., 1990; Langer et al., 1993; van Hinsbergh, 1992). 
The formation of capillary structures in three-dimen- 
sional matrices of fibrin and collagen has been studied in 
vitro with bovine  endothelial cells  (Pepper  et al.,  1990; 
Madri et al., 1991; Montesano, 1992; Goto et al., 1993) and 
rat aorta explants (Nicosia and Ottinetti, 1990). Pepper et 
al. (1990) demonstrated that the formation of capillary-like 
tubular structures in a three-dimensional fibrin or collagen 
matrix is induced by addition of bFGF and counteracted 
by TGF[3. In these bovine endothelial cells bFGF induces 
both u-PA activity and u-PAR expression, whereas TGFI3 
predominantly enhanced PAI-1. A reproducible model to 
study the formation of capillary-like structures in fibrin 
matrices with human endothelial cells has not yet been 
available. Although bFGF also enhances u-PAR expres- 
sion in human endothelial cells (Mignatti et al., 1991), it is 
still unable to increase u-PA expression in these endothe- 
lial cells (see below). 
We have investigated the minimal requirements for hu- 
man endothelial cells to form capillary-like tubular struc- 
tures in three-dimensional fibrin matrices. Our data indi- 
cate  that in  addition to angiogenic growth factor(s),  an 
inflammatory mediator, TNFet,  is required  and u-PAR- 
bound u-PA activity is involved in the formation of capil- 
lary-like tubular structures of human microvascular endo- 
thelial cells in these fibrin matrices. 
Materials and Methods 
Materials 
Medium 199 (M199) supplemented with 20 mM Hepes was obtained from 
Flow Labs. (Irvine, Scotland); tissue culture plastics and Transwell sys- 
tems were from Costar (Cambridge, MA).  Penicillin/streptomycin and 
bFGF was purchased from Boehringer Mannheim (Mannheim, FRG). A 
crude preparation of endothelial cell growth factor was prepared from bo- 
vine hypothalamus as described by Maciag et al.  (1979).  Human serum 
was obtained from a local bloodbank and was prepared from fresh blood 
from 10-20 healthy donors, pooled, and stored at 4°C; it was not heat- 
inactivated before use. Newborn calf serum (NBCS) was obtained from 
GIBCO BRL (Gaithersburg, MD), heparin and thrombin from Leo Phar- 
maceutics Products (Weesp, The Netherlands), human fibrinogen from 
Chromogenix AB (M/51ndal, Sweden) and horseradish peroxidase (HRP) 
from Sigma Chem. Co. (St. Louis, MO). Factor XIII was generously pro- 
vided by Dr. H. Keuper (Behringwerke, Marburg, Germany), human re- 
combinant VEGF165 was prepared as described (Fiebich et al., 1992). Hu- 
man recombinant TNFct was a gift from Dr. J. Travernier (Biogent, Gent, 
Belgium) and contained 2.45 x  107 U/mg protein and <40 ng lipopolysac- 
charide per p~g protein. Rabbit polyclonal anti-u-PA antibodies and rab- 
bit polyclonal anti-t-PA antibodies were prepared in our laboratory. Sin- 
gle-chain  u-PA  (Orsini  et  al.,  1991)  was  kindly  provided by  Dr.  A. 
Molinari (Farmitalia, Carlo Erbe, Milan, Italy), the amino terminal frag- 
ment of u-PA (ATF: amino acids 1-143) was provided by Abbott (Abbott 
Park, IL). Tyrphostin A47 was obtained from LC Laboratories (Woburn, 
MA). Aprotinin was purchased from Pentapharm Ltd. (Basel, Switzer- 
land), e-aminocaproic acid (~-ACA) was purchased from Merck (Darms- 
tadt, Germany) and CHO cell supernatant containing soluble u-PA receptor 
(Wilhelm et al., 1994) was a gift from Dr. U. Weidle (Boehringer-Mann- 
helm, Penzberg, Germany). Purified soluble u-PAR was obtained by af- 
finity chromatography using u-PA-coupled Sepharose (>95 % pure as de- 
termined using SDS-PAGE analysis). 
Cell Culture 
Human  foreskin microvascular endothelial cells (hMVEC)  and human 
umbilical vein endothelial cells (HUVEC) were isolated, cultured, and 
characterized as previously described (Van Hinsbergh et al., 1987, 1990; 
Defilippi et al., 1991a). Cells were cultured on fibronectin-coated dishes in 
M199 supplemented with 20 mM Hepes (pH 7.3),  10%  human serum, 
10% heat-inactivated NBCS, 150 p,g/ml crude endothelial growth factor, 5 
U/ml heparin, 100 IU/ml penicillin, and 100 ~g/ml streptomycin at 37°C 
under 5%CO2/95% air atmosphere. 
For the evaluation of the role of TNFct,  bFGF, and VEGF165 on the 
production of u-PA, tissue-type plasminogen activator (t-PA) and PAI-1, 
and on the u-PA receptor expression, hMVEC were cultured on fibronec- 
tin-coated culture dishes without growth factor for 2 d. Thereafter, the en- 
dothelial cells were stimulated with bFGF, VEGF165, or TNFa in M199 
supplemented with 10% human serum and penicillin/streptomycin  for 24 h. 
The supernatants were collected for the determination of u-PA antigen, t-PA 
antigen, and PAL1 antigen by ELISA; the cells were used to determine 
the u-PA-binding capacity (see below). 
ELISAs 
u-PA ELISA.  The monoclonals used in this ELISA were produced in our 
laboratory, and recognized single-chain u-PA, two-chain u-PA, and the 
u-PA/PAI-1 complex with comparable efficiency. 96-well microtiter plates 
were coated overnight at room temperature with 100 ixl of a mixture of 
two monoclonal antibodies, UK 2.1 and UK 26.15, recognizing different 
epitopes on the u-PA antigen (0.5 ~g/ml each in phosphate buffered sa- 
line, PBS). After washing with PBS-0.02% Tween 20 (PBS-T), the plates 
were incubated for 1 h with 150 p,l of 0.1%  (wt/vol) casein in PBS-T to 
block  nonspecific protein binding to  the plates. The  plates were then 
washed three times with PBS-T and 100/~l of serial dilutions of standard 
u-PA (UKIDAN®,  Serono, Aubonne, Switzerland, assuming that  one 
unit, as determined by the manufacturer, is 10 ng protein) or culture su- 
pernatant were added. After 2 h  at 37°C, the plates were washed three 
times and incubated with 100  p,1 of a  biotinylated anti-u-PA antibody 
(LMW 11.1, 0.4 ~g/ml in PBS-T containing 0.1% casein) for 1.5 h at 37°C, 
followed by a 1-h incubation with 100 p,l of HRP conjugated to avidin 
(1:5,000; Pierce Chem. Co., Rockford, IL). Finally, the plates were washed 
four times with PBS-T, and 100 p,l of tetramethylbenzidine substrate was 
added to react and the reaction was stopped with 50 Ixl 2 M H2SO  4 after 15 
min incubation at room temperature. The extinction at 450 nm was measured 
with a multichannel speetrophotometer (Titertek multiscan, Flow Labs.). 
PAl-1 ELISA.  Levels of PAI-1 antigen in endothelial cell conditioned 
media  were  assayed  by  ELISA  (IMULYSEa'MPAI-1)  obtained  from 
Biopool (Umea, Sweden), according to the manufacturer's description. 
t-PA ELISA.  Assay of t-PA antigen was performed with the ELISA 
Thrombonostika  t-PA  (Organon-Teknika,  Turnhout,  Belgium)  as  de- 
scribed by Bos et al. (1992). In this assay, free t-PA and t-PA:PAI-1 com- 
plexes are detected with equal efficiency. 
Determination of Specific u-PA Binding 
Diisopropylfiuorophosphate-treated u-PA  (Ukidan®)  (DIP-u-PA)  was 
radiolabeled using Na125I according to  the Iodogen procedure  (Pierce 
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The cells were placed on melting ice and incubated for 10 min with 50 rnM 
glycine-HC1 buffer (pH 3.0) to remove receptor-bound endogenous u-PA. 
Subsequently, the cells  were washed twice  with ice-cold  M199  medium 
and incubated with 8 nM or the indicated amount of 125I-DIP-u-PA in en- 
dothelial  cell-conditioned  medium  (M199  medium supplemented with 
1% human serum albumin, conditioned for 24 h) for 3 h. Incubation was 
performed in endothelial  cell--conditioned  medium to exclude  residual 
binding of u-PA to cell-associated  PAL1. In parallel incubations, a 50-fold 
excess of DIP-u-PA was included to assess nonspecific binding. After the 
incubation period,  unbound ligand  was removed by extensive washing 
with ice-cold  PBS.  Cell-bound ligand was solubilized with 0.3 M NaOH, 
and the radioactivity was determined in a ~-counter (Cobra Auto gamma, 
Packard).  Specific  binding was calculated  by subtraction of nonspecific 
binding from the total binding. 
Incorporation of [3HlThymidine 
Incorporation of [3H]thymidine  in DNA was determined as previously de- 
scribed (Van Hinsbergh et al.,  1983). Confluent cultures of endothelial 
cells were detached by trypsinfEDTA solution, and seeded at a density of 
104  cells  per cm  2 on fibronectin-coated  dishes in M199-Hepes  medium 
supplemented with 10% heat-inactivated newborn calf serum and penicil- 
lin/streptomycin with or without 20  ng/ml bFGF. After a preincubation 
period of 18 h, a tracer amount of [3H]thymidine  (0.5 p,  Ci per 2 cm  2 well, 
added in a 10-p.l vol) was added and the cells were incubated for a 6-h pe- 
riod. Subsequently, the cells were washed with PBS, and 3H-labeled  DNA 
was precipitated in 10%  trichloroacetic acid,  washed twice  in 96%  etha- 
nol, dissolved in 0.3 ml 0.3 M NaOH and counted in a liquid scintillation 
counter. 
In Vitro Angiogenesis Model 
Human fibrin matrices were prepared by addition of 0.1 U/ml thrombin to 
a mixture of 5 U/ml factor XIII (final concentrations), 2 mg fibrinogen, 2 mg 
Na-citrate, 0.8 mg NaCI and 3 p,g plasminogen per ml M199 medium. 300 
or 600 }xl of this mixture was added to the wells of 48 or 24-well plates, re- 
spectively.  After clotting at 37°C, the fibrin matrices were soaked with 
M199 supplemented with 10%  human serum and 10%  NBCS for 2 h at 
37°C to inactivate the thrombin. Highly confluent endothelial cells  were 
detached and seeded in a 1:1 split ratio on the fibrin matrices and cultured 
for 24 h  in M199  medium supplemented with 10%  human serum, 10% 
NBCS, and penicillin/streptomycin. Then, the endothelial cells were cul- 
tured with either of the mediators indicated for 8--12 d. The culture me- 
dium was collected  and replaced every 2 or 3 d. Invading cells and the for- 
mation of tubular structures of endothelial ceils in the three-dimensional 
fibrin matrix were analyzed by phase contrast microscopy and the total 
number, the total area and the total length of tubelike structures of six 
randomly chosen microscopic fields/well  (7.3 mm2/field)  were measured 
using a Nikon FXA microscope equipped with a monochrome CCD cam- 
era (MX5) connected to a  computer with Optimas image analysis soft- 
ware. All three measured parameters correlated well with each other (r > 
0.96). The formation of tubular structures of endothelial cells in the three- 
dimensional fibrin matrix was also analyzed by histological  examination 
after fixation of the matrices as described below. Inhibition experiments 
were performed by the addition of either 100 KIU/ml aprotinin, 0.5 i~g/ml 
soluble u-PA receptor, 10 p,g/ml tyrphostin A47, rabbit polyclonal anti-u- 
PA (1:100 serum dilution), rabbit polyclonal anti-t-PA (1:100 serum dilu- 
tion), nonimmune rabbit serum (1:100 serum dilution), or 5 mM e-ACA to 
the culture medium. 
Histological Analysis 
Electron Microscopy.  For electron  microscopy, the  fibrin matrices were 
fixed and treated as described by Murray et al. (1991). Briefly,  the matri- 
ces were fixed  with 2%  glutaraldehyde in 0.15 M  Na-cacodylate buffer 
(pH %4), postfixed in  1%  osmium tetroxide in the same buffer, dehy- 
drated by a graded series of ethanol and embedded in Epon (LX resin, 
Ladd Research Industries Inc., Burlington, VT) as described (Murray et 
al.,  1991). The embedded matrices were cut (0.1 I~m)  perpendicularly to 
the surface of the matrix sheet, stained with uranyl acetate and lead cit- 
rate, and finally analyzed using a Philips EM 410 electron microscope. 
Light Microscopy.  After overnight fixation at 4°C with 10%  formalin 
and amidoblaek I0B (0.1% wt/vol), the matrices were washed three times 
in aquadest, dehydrated by a graded series of ethanol, and embedded in 
glycol methacrylate as described (Gerrits et al., 1991). The embedded ma- 
trices were cut (3 Ixm) perpendicularly to the surface of the matrix sheet, 
stained with 0.1% haematoxylin, and analyzed. 
Statistical Analysis 
Statistical  significance  of differences were tested by one-way Anova anal- 
ysis followed by Dunnett's Multiple Comparisons  Test. 
Results 
Effects of bFGF, VEGF165,  and TNFa on the 
Production of  Plasminogen Activators and PAl-1 by 
Human Microvascular  Endothelial Cells 
When  human  foreskin  microvascular  endothelial  cells 
(hMVEC) were stimulated for 24 h with various concen- 
trations of TNFet, a dose-dependent increase of u-PA anti- 
gen production was found (Fig. 1 A). However, incubation 
of hMVEC  with VEGF~65  or bFGF did not change  the 
production of u-PA  antigen,  or  even slightly decreased 
u-PA accumulation in the conditioned medium (Fig. 1 A). 
A similar pattern was seen in the production of PAI-1 an- 
tigen by hMVEC (Fig. 1 B). 
The production of t-PA by hMVEC was  dose depen- 
dently stimulated by the addition of VEGF165 or TNFot but 
not by bFGF (Fig. 1 C). The VEGF165- and TNFet-induced 
increase in t-PA production was consistently observed in a 
number of hMVEC cultures derived from different donors 
and was also found at the mRNA level (data not shown). 
Whereas VEGF165 enhanced t-PA synthesis in HUVEC, 
TNFa  did  not  increase  t-PA  mRNA  and  synthesis  in 
HUVEC,  in agreement with previous observations (van 
Hinsbergh et al., 1990). 
Simultaneous  incubation  of  hMVEC  with  bFGF  or 
VEGF165 did not influence the TNFet-induced production 
of u-PA, t-PA, or PAI-1 by hMVEC after 24 h of incuba- 
tion significantly (data not shown). 
Effects of  bFGF, VEGF165,  and TNFa on the 
Expression of u-PA Receptors on hMVEC 
The number of u-PARs on hMVEC was determined from 
the  binding  of  t25I-DIP-u-PA  to  these  cells,  bFGF  in- 
creased the specific binding of t25I-DIP-u-PA to hMVEC 
in a concentration-dependent way (Fig. 1 D, Table I). Com- 
parably, VEGF165 induced an increase in specific 125I-DIP- 
u-PA binding to hMVEC (Fig. 1 D, Table I). This effect 
was detectable from a concentration of 1-10 ng/ml VEGF165, 
maximal at 50-100 ng/ml VEGFt65, and was identical in 
the presence or absence of heparin (not shown). The ef- 
fects of bFGF and VEGF165 were additive (Fig. 1 D). Scat- 
chard analysis of the t25I-DIP-u-PA-binding data revealed 
one type of binding site on hMVEC (Fig. 2). The number 
of 125I-DIP-u-PA-binding sites increased from 3.8  ×  104 
sites per endothelial cell to 5.6 ×  104, 6.3  ×  104, and 9.1 × 
104 per cell after incubation with 20 ng/ml bFGF, 100 ng/ 
ml VEGFt65, or bFGF and VEGFt65, respectively. The af- 
finity of the u-PAR was not significantly altered by incu- 
bation with bFGF and/or VEGF16s and ranged from 2.0 
nM to 2.9 nM under the various conditions. Cross-linking 
of 125I-DIP-u-PA with endothelial cell membrane proteins 
resulted in the formation of a complex of 100 kD (the mo- 
lecular mass of the u-PA:u-PA receptor complex) in un- 
treated and VEGF- or bFGF-treated ceils (not shown). 
Koolwijk et al. TNFa and Capillary Tube Formation  1179 Figure 1.  Effect of bFGF, VEGF165, and TNFct on 125I-DIP-u-PA  binding to and the production of u-PA, t-PA, and PAI-1 by hMVEC. 
hMVEC were stimulated for 24 h with the indicated amounts of bFGF, VEGF165, TNFa, or the combination of 50 ng/ml bFGF and 100 
ng/ml VEGF165. The amount of (A) u-PA antigen, (B) PAI-1 antigen, and (C) t-PA antigen in the supernatants  was determined  by 
ELISA. The number of u-PAR (D) was determined by the binding of 125I-DIP-u-PA  to the hMVEC as described in Materials and Meth- 
ods. The data represent mean +SD of triplicate wells and are representative for three experiments. 
An increase in 125I-DIP-u-PA binding was also detected 
after incubation of hMVEC with TNFa (Fig. 1 D; Table I). 
This was observed in seven independent hMVEC cultures 
(130  _  40%  increase, mean  _  SD),  whereas  it was not 
found in four independent cultures of HUVEC (83 + 4%). 
Effect of bFGF, VEGF16~, and TNFa on Angiogenesis 
In Vitro 
To investigate the ability of bFGF, VEGF165, and TNFet to 
induce  human  endothelial  cell  tube  formation  in  vitro, 
hMVEC were cultured on three-dimensional fibrin matri- 
ces in the continuous presence of 50 ng/ml bFGF, 100 ng/ 
ml VEGF16s, 4 ng/ml TNFc~, or combinations of these me- 
diators. After 8-10 d of culture, invading cells and the for- 
mation  of tubular  structures  of endothelial  cells  in  the 
three-dimensional fibrin  matrix were  analyzed by phase 
contrast microscopy, and, after fixation of the matrices, by 
histological examination of cross-sections. In unstimulated 
cultures and in cultures stimulated with TNFot,  confluent 
monolayers of endothelial  cells  remained  on top  of the 
three-dimensional fibrin matrix, but invading endothelial 
cells  and tubular structures in the fibrin matrix could not 
be observed (Fig.  3, a and b, and 4 a). Addition of bFGF, 
VEGF:65, or the  combination of bFGF and  VEGFa65 to 
the hMVEC induced an increase in the number of endo- 
thelial cells  on the fibrin matrix (130--155%  of control af- 
ter  stimulation  with  VEGF165  or  bFGF,  respectively). 
125  Table I. Binding of  I-DIP-u-PA to Human Endothelial Cells 
Binding of ~25I-DIP-u-PA (Percent of control) 
Addition  hMVEC  HUVEC 
None  100  (n  =  8)  100  (n =  17) 
(2.6 ±  1.3 fmol/  (6.4 _  3.2 fmol/ 
105 cells)  105 cells) 
bFGF (20 ng/ml)  172 -+ 25*  (n =8)  178 ±  33*  (n =  17) 
TNFct (20 ng/ml)  130 -+ 40  (n =  7)  83 ±  4  (n =  4) 
VEGF (I00 ng/ml)  146 --- 40  ~  (n =  6)  156 ±  27*  (n =  4) 
Binding of 1251-DIP-u-PA to hMVEC was determined at 0°C. Receptor-bound endog- 
enous u-PA was removed by pH treatment as described in Materials and Methods. Af- 
ter washing, the cells were incubated with 7.5 nM 125I-DIP-u-PA for 3 h. In parallel in- 
cubations a 50-fold excess of unlabeled DIP-u-PA was included to assess nonspecific 
binding. Unbound ligand was removed by extensive washing with ice-cold PBS. Cell- 
bound ligand was solubilized in 0.3 M NaOH, and radioactivity was determined in a 
"t-counter. Specific binding was calculated by subtraction of nonspecific binding. The 
data represent the mean -+SD. 
*P <  0.01. 
~P <  0.05. 
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Figure 2.  Scatchard  analysis of the binding  of 125I-DIP-u-PA to 
hMVEC, hMVEC were preincubated for 24 h in M199 medium, 
10% human serum supplemented with 20 ng/ml bFGF (&), 100 
ng/ml VEGF165 (E]), 20 ng/ml bFGF plus 100 ng/ml VEGF165 (V), 
or without growth factor (©). Subsequently,  the cells were cooled 
on ice and binding of 125I-DIP-u-PA was performed as described 
in the Materials  and Methods section. The results of the binding 
of z25I-DIP-u-PA are shown in the inset. 
However, these growth factors failed to induce the forma- 
tion of tubular structures of endothelial cells in the fibrin 
matrix  (Fig.  3,  c-e).  When  TNFa  was  added  simulta- 
neously with bFGF or VEGF165  to the hMVEC monolay- 
ers, the formation of tubular structures was induced (Fig. 
3, fand g), whereas the number of endothelial cells on top 
of the fibrin matrix was not significantly changed (95% of 
control) compared with nonstimulated conditions. Control 
experiments revealed that the  amount of TNF0t used  in 
the  experiments  completely  inhibited  the  bFGF-  and 
VEGF165-induced  increase in endothelial cell number on 
top of the fibrin matrix (data not shown). The growth of 
the  tubular  structures  started  after 4-5  d  of stimulation 
and was optimal at day 8-10 after continuous stimulation 
of the endothelial cell monolayers. However, when hMVEC 
were stimulated with VEGF165,  bFGF, and TNFa simulta- 
neously, a more than additive effect of these factors was 
observed (Fig. 3 h and Fig. 4 b). 
Dose-response experiments using VEGF165  and  bFGF 
in the presence of 4 ng/ml TNFa showed that the minimal 
concentration of VEGF~65 and bFGF to induce formation 
of tubular structures of hMVEC was 10 ng/ml and 0.5 ng/ 
ml, respectively, whereas the maximal formation of tubu- 
lar structures  in the presence of 4  ng/ml TNFct required 
the  combination  of  100  ng/ml  VEGF165  and  50  ng/ml 
bFGF (data not shown). 
Histological analysis of the cross-sections perpendicular 
to the surface of the matrix showed that these capillary- 
like  structures  were  located  in  the  fibrin  matrix  under- 
neath  the  endothelial  cell  monolayer. The  capillary-like 
structures consist of hMVEC surrounding a lumen (Fig. 4 
d,  arrows). Electron  microscopy analyses  revealed  that 
these hMVEC had cellular polarization, pinocytotic vesi- 
cles at the lumenal side, and a basement membrane at the 
basolateral side of the cell (data not shown). Furthermore 
these electron microscopy analyses of capillary-like struc- 
tures of hMVEC revealed remodeling of the fibrin matrix at 
the basolateral side of the endothelial cells (Fig. 4 e, arrows). 
Similar results were obtained when two other strains of 
hMVEC from different donors were used. When five dif- 
ferent HUVEC isolations were used, heterogenous results 
were obtained.  Three cultures formed tubular structures 
just like the three hMVEC cultures: only after the addition 
of TNFot in combination with bFGF and/or VEGF165.  One 
HUVEC isolation did not invade the fibrin matrix, even 
after the addition of bFGF, VEGF165  and TNFt~, whereas 
the fifth HUVEC culture formed tubular structures spon- 
taneously (data not shown). 
Long-Term Effect of bFGF, VEGF165,  and TNFa 
on the Production of u-PA and PAI-1 by Human 
Microvascular Endothelial Cells 
The secretion of u-PA and PAI-1 by the hMVEC cultured 
on the fibrin matrix was followed during the time period of 
the formation of tubelike structures of these hMVEC. The 
u-PA  concentration  in  the  supernatants  of unstimulated 
hMVEC  did not increase significantly during the culture 
period of 10 d  (Fig. 5 A). Incubation of the hMVEC with 
bFGF, VEGF165,  or the combination of these two growth 
factors did not induce an increase in u-PA production. The 
initial accumulation of u-PA in the endothelial cell condi- 
tioned medium during the first 24-h incubation of hMVEC 
with TNFa (Fig. 1), disappeared during prolonged incuba- 
tion of hMVEC with TNFet. However, the PAI-1 produc- 
tion rate continued to increase during the 10-d culture pe- 
riod in the presence of TNFa (Fig. 5 B). We observed a 
continued increase in the u-PA production rate by hMVEC 
when TNFa was added in combination with either bFGF 
or VEGF165,  or both growth factors (Fig. 5 A). Similarly, 
PAI-1 antigen production rate by the hMVEC increased 
during this culture period (Fig. 5 B). 
Role of Plasminogen Activators,  u-PA Receptor, and 
Plasmin during In Vitro Angiogenesis 
The role of u-PA, t-PA, and the role of the expression of 
u-PAR  during  the  formation  of  tubular  structures  of 
hMVEC in the fibrin matrices was studied by the addition 
of u-PA or t-PA specific antibodies which inhibit PA activ- 
ity and by the addition of soluble u-PAR. Both the u-PA 
specific polyclonal antibodies, the soluble u-PAR contain- 
ing CHO supernatant, and affinity-purified soluble u-PAR 
inhibited  the  formation of tubular  structures  (Table II). 
Furthermore, there was also a decrease in the diameter of 
the tubes after the addition  of the u-PA inhibitors  (data 
not  shown).  In contrast,  polyclonal antibodies  inhibiting 
t-PA activity, preimmune serum and control supernatants 
of CHO  cells  did  not  inhibit  the  formation  of tubelike 
structures  significantly.  Addition  of aprotinin  or ¢-ACA 
also inhibited the formation of tubular structures for ~71- 
95 %, respectively, indicating that plasmin activity, which is 
probably generated by u-PA, is also involved in the forma- 
tion of tubular structures in the fibrin matrix. When fibrin 
matrices were made using plasminogen-depleted fibrino- 
gen, no ingrowth of endothelial cells and formation of tu- 
bular structures was observed (data not shown). 
Koolwijk  et al.  TNFot and Capillary  Tube Formation  1181 Figure 3.  In vitro angiogenesis induced by bFGF, VEGF165, and TNFct. hMVEC were cultured on the surface of a three-dimensional  fi- 
brin matrix in M199 medium supplemented with 10% human serum and 10% NBCS and stimulated without (a) or with 4 ng/ml TNFa 
(b), 50 ng/ml bFGF (c), 100 ng/ml VEGF165 (d), bFGF and VEGF165 (e), bFGF and TNFct (f), VEGFi65, and TNFot (g), or the combina- 
tion of all three mediators (h). After 10 d of culture, nonphase contrast views were taken; the plane of focus is beneath the endothelial 
surface monolayer. Bar represents 500/.tm. 
The Journal  of Cell Biology, Volume 132, 1996  1182 Figure 4.  In vitro angiogenesis induced by bFGF, VEGF165, and TNFct. hMVEC were cultured on the surface of a three-dimensional fi- 
brin matrix in M199 medium supplemented with 10% human serum and 10% NBCS and stimulated with (b, d, and e) or without (a and 
c) the combination of bFGF (50 ng/ml), VEGF165 (100 ng/ml), and TNFc~ (4 ng/ml). (a and c) After 10 d of culture, phase contrast photo- 
micrographs were taken; the plane of focus is beneath the endothelial surface monolayer. (c and d) Histological examination of 3 Ixm 
cross-sections perpendicular to the matrix surface was performed. Lumens surrounded by endothelial cells are indicated by arrows. 
Magnification 25. (e) Electron microscopy analysis of a tubelike structure of microvascular endothelial cells was performed. Remodeling 
of the fibrin matrix is observed at the basolateral side of the endothelial cells (arrows).  Magnification 5,000. Bar, 150 txm. 
Formation of Tubelike Structures of hMVEC 
by Simultaneous Addition of  bFGF, VEGF165,  and 
Single-Chain u-PA 
An increase  of u-PA (induced  by TNFet in combination 
with bFGF and VEGF165)  and the presence of u-PAR (en- 
hanced by bFGF and VEGF165) seems to be required  for 
the formation of tubelike  structures of hMVEC in the fi- 
brin  matrix.  To  investigate  whether  the  production  of 
u-PA by bFGF-  and VEGF165-stimulated  hMVEC  is  the 
limiting  step  in  the  formation  of the  tubelike  structures, 
exogenous single-chain  u-PA (scu-PA) was added  to the 
hMVEC cultured on the fibrin matrix. Addition of scu-PA 
to unstimulated  hMVEC or hMVEC stimulated  with low 
doses of bFGF and VEGF165, which are sufficient  to in- 
duce mitogenicity but cause a moderate increase in u-PAR, 
did  not  significantly  induce  the  formation  of  tubelike 
structures (Fig. 6). However, addition of 10 ng/ml scu-PA 
to hMVEC stimulated  with higher amounts of bFGF and 
VEGF165 resulted  in the formation of tubelike  structures 
in the fibrin matrix. The total length of these induced tube- 
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Figure 5.  u-PA and PAL1 production by long-term hMVEC cultures  on fibrin matrices,  hMVEC were cultured  on the surface of a 
three-dimensional  fibrin matrix in M199 medium supplemented with 10% human serum and 10% NBCS (lq), and stimulated with bFGF 
(50 ng/ml, A), VEGF165 (100 ng/ml, O), TNFct (4 ng/ml, +), bFGF and VEGF165 (V), bFGF and TNFa (1), VEGF165 and TNF<x (e), or 
bFGF, VEGF165 and TNFa (T). u-PA and PAI-1 antigen was determined by ELISA as described and the production was expressed as 
ng/24 h (production  rate) or ng/well (cumulative production).  Similar results were obtained in four independent experiments. 
like structures was higher as compared to that induced by 
the  addition  of TNFa.  Addition  of the  amino  terminal 
fragment (ATF) of u-PA did not induce the outgrowth of 
tubular structures in the fibrin matrix (Fig. 6). 
Mitogenesis Stimulates but Is Not Essential  for the 
Formation of Tubular Structures 
Both bFGF and VEGF~65 are mitogenic factors for human 
endothelial cells. Maximal [3H]thymidine incorporation is 
reached at 1-4 ng/ml bFGF or VEGF165 (data not shown), 
a much lower concentration needed to increase u-PAR ex- 
pression.  This  suggests  that  different  receptors  are  in- 
volved in  the  mitogenesis  and  the  induction  of u-PAR. 
This suggestion is further strengthened by the observation 
that [3H]thymidine incorporation and cell proliferation in- 
duced by bFGF or VEGF165 are inhibited by the tyrosine ki- 
nase inhibitor tyrphostin A47 (Fig. 7 A), whereas the induc- 
tion of the u-PAR is not affected by this inhibitor (Fig. 7 B). 
To investigate whether endothelial  cell proliferation is 
important in  our in  vitro angiogenesis  model, we  added 
the tyrphostin A47 to hMVEC stimulated with a combina- 
tion of bFGF, VEGF165,  and TNFa. Addition of 10 ixg/ml 
tyrphostin A47, inhibited the bFGF- and VEGF-induced 
hMVEC proliferation completely (Fig. 7 A) but did not af- 
fect the expression of the u-PAR (Fig. 7 B), u-PA, or PAI-1 
expression  (data  not  shown).  This  concentration  of tyr- 
phostin A47 reduced the formation of tubular structures in 
the fibrin matrix for 28-36%  only (Table II). Control ex- 
periments indicated that the amount of tyrphostin A47 in 
the conditioned media after 48 or 72 h incubation was still 
sufficient to completely inhibit  basal and  bFGF-induced 
[3H]thymidine incorporation in endothelial cells (data not 
shown). This indicates that proliferation is not essential for 
the formation of tubular structures of human endothelial 
cells. 
Discussion 
Fibrin, angiogenic factors, and inflammatory cells are com- 
monly present in pathological forms of angiogenesis in the 
adult.  In this study we report that, in addition  to angio- 
genic  growth  factors  bFGF  and  VEGF165,  the  cytokine 
TNF~  is  required  to  induce  capillary-like tubular  struc- 
tures of hMVEC in a three-dimensional fibrin matrix. 
Furthermore, we demonstrate that the contribution  of 
TNFo~, which among many other effects induces u-PA pro- 
duction  (van Hinsbergh et al., 1990), is mainly due to its 
ability to increase receptor-bound  u-PA activity because 
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Experiment 1  Experiment 2  Experiment 3 
Addition  tube length  inhibition  tube length  inhibition  tube length  inhibition 
None 
bFGF +  VEGFI65 +  TFNct 
bFGF +  VEGF165 +  TFNct 
+  anti-u-PA serum 
+  anti-t-PA serum 
+  preimmune serum 
+  soluble u-PA receptor 
+  aprotinin 
+  ~-ACA 
+  tyrphostin A47 
/zm  %  ~  %  /am  % 
6333 ±  4033  2667 ±  767  1040 ±  227 
106833 ±  10000  105167 ±  7887  148073 ±  18007 
16667 ±  2500*  90  22667 ±  1153"  80  3107 ±  433*  99 
ND  86500 ±  16933  18  153460±  16653  4 
ND  70667 ±  11167  33  145867 ±  28800  1 
48000±  2033*  59  5167 ±  2180"  96  12440 ±  7753*  92 
35167 ±  11553*  71  8833 ±  1687"  94  ND 
ND  7553 ±  3087*  95  ND 
68833 ±  7320  36  73404±  10980  31  106465 ±  5587  28 
Human MVEC were cultured on the surface of a three-dimensional fibrin matrix in M199 medium supplemented with 10% human serum and 10% NBCS and stimulated with the 
combination of bFGF (50 ng/ml), VEGFj65 (100 ng/ml), and TNFet (4 ng/ml) with or without blocking anti-u-PA antiserum, anti-t-PA antiserum or preimmune serum (l: 100 di- 
lution), 0.5 p.g/ml soluble u-PA receptor (CHO superuatant [Exps. l and 2] and affinity-purified [Exp. 3]), 100 KIU/ml aprotinin, 5 mM ~-ACA, or 10 p.g/ml tyrphostin A47. After 
10-12 d of culture, phase contrast photomicrographs  were taken and the total length of tubelike structures was measured using a microscope equipped with a monochrome CCD 
camera (MX5) connected to a computer with image analysis software. The data represent the mean length/cm  2 _+ SEM of triplicate (Exp. 1) or duplicate (Exps. 2 and 3) wells. 
*P <  0.01. 
*P <  0.05. 
u-PA but not its amino terminal fragment (ATF) can re- 
place TNFa, and the formation of tubular structures is in- 
hibited by anti-u-PA antibodies, soluble u-PAR, and plas- 
min inhibitors. 
Our data closely agree with previous studies of Pepper 
et al. (1990, 1992) who demonstrated with bovine adrenal 
microvascular endothelial cells that bFGF or VEGF165 en- 
hanced endothelial cell migration and formation of capil- 
lary-like structures in a fibrin matrix by stimulation of re- 
ceptor-bound u-PA activity, and that these growth factors 
acted synergistically to each other. On the other hand, our 
data  seem to  contrast  with  these  studies  (Pepper et  al., 
1990,  1992) because bFGF and VEGF165  themselves were 
unable to induce tubelike structures of hMVEC. This dif- 
ference  can  be  explained  by  the  fact  that  bFGF  and 
VEGF165  are potent inducers of both u-PA and u-PAR in 
bovine cells (Saksela et al., 1987; Pepper et al., 1991, 1993), 
but bFGF and VEGF165 do not enhance u-PA production 
in  human  endothelial  cells  (Bikfalvi  et  al.,  1991;  this 
study). However, a combination of angiogenic growth fac- 
tor(s) and TNFet, which is a strong inducer of u-PA in hu- 
man endothelial cells (van Hinsbergh et al., 1990; Niedbala 
et al., 1992) provides the requirements needed for the for- 
mation of capillary-like structures of hMVEC in vitro. 
TNFa has multiple effects on endothelial cells, including 
the induction  of leukocyte adhesion  molecules (Bevilac- 
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Figure 6.  Formation of tube- 
like structures  of hMVEC by 
simultaneous  addition  of 
bFGF, VEGFt65, and single- 
chain  u-PA.  hMVEC  were 
cultured  on the surface  of a 
three-dimensional fibrin ma- 
trix in M199 medium supple- 
mented with 10% human se- 
rum  and  10%  NBCS  and 
stimulated with the combina- 
tion  of bFGF,  VEGF165 (as 
indicated),  and either TNFa 
(4 ng/ml),  single-chain  u-PA 
or  ATF  (10  ng/ml).  Total 
tube-length/cm Z _+ SEM was 
determined of triplicate wells 
as described. 
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Figure 7.  Induction  of mitogenesis  and  u-PAR  expression  by 
bFGF and VEGF165 proceed by different pathways. Effect of the 
tyrosine kinase inhibitor tyrphostin A47 on basal and bFGF and/ 
or VEGF165 induced proliferation and pericellular  u-PA expres- 
sion of hMVEC.  (A) Subconfluent  hMVEC were cultured  in the 
absence ([~) and presence (i) of 20 ng/ml bFGF for 18 h in the 
presence of increasing  amounts of tyrphostin A47. After 18 h, a 
tracer amount of [3H]thymidine was added to the medium and 
the incubation continued  in the same medium for another 6 h and 
[3H]thymidine incorporation was determined as described  in the 
Materials and Methods section. (B) Confluent hMVEC were cul- 
tured for 24 h in M199 medium supplemented with 10% human 
serum (El) or in M199 supplemented with 10% human serum and 
50 ng/ml bFGF and 50 ng/ml VEGF165 (i).  u-PAR expression 
was determined by the binding of 125I-DIP-u-PA to the endothe- 
lial cells as described in the legend of Fig. 2. 
qua et al., 1994), induction of inducible forms of cyclooxy- 
genase and nitric oxide synthase (Hla and Neilson, 1992; 
Gross et al., 1992), enhanced expression of integrins (De- 
filippi et al.,  1991a,b),  inhibition  of mitogenesis (Frat~r- 
SchrOder et al., 1987; Cavender et al., 1989), and induction 
of  u-PA  and  PAI-1  (van  Hinsbergh  et  al.,  1988,  1990; 
Schleef et al., 1988). Our observation that soluble u-PAR 
and antibodies, which inhibit u-PA activity, markedly in- 
hibited the formation of capillary-like structures, suggests 
a role of TNFa-induced u-PA. This suggestion is strength- 
ened by the finding that,  similar to TNFa,  u-PA can in- 
duce the outgrowth of tubular structures but only in the 
presence of bFGF and/or VEGF165.  It is likely that the ef- 
fect of u-PA involves proteolytic activation of plasmino- 
gen by receptor-bound u-PA because the ATF of u-PA, 
which binds  similarly to the u-PAR receptor but has no 
proteolytic activity, was inactive. Furthermore, inhibition 
of plasminogen activation by ~-ACA, inhibition of plasmin 
activity by aprotinin  or plasminogen withdrawal  also re- 
duced the outgrowth of tubular structures. 
bFGF and VEGF increased the  number of u-PAR  in 
human endothelial cells (Mignatti et al., 1991; this study). 
Although this may contribute to an increase in u-PA activ- 
ity on the cell surface, it is unlikely that the effect of the 
angiogenic growth  factors on  the  stimulation  of tubular 
outgrowth is mainly due to u-PAR enhancement. TNFct, 
which in hMVEC causes a 30% increase in u-PAR in addi- 
tion to inducing u-PA synthesis, had no effect when it was 
added to the cells alone, bFGF and VEGF both are potent 
mitogens for hMVEC. However, it is unlikely that stimula- 
tion  of  mitogenesis  is  the  predominant  effect  of  these 
growth factors because little cell proliferation is observed 
in the presence of TNFet, and a  potent inhibitor of both 
bFGF-  and  VEGF-induced  mitogenesis  tyrphostin  A47 
had only a moderate inhibitory effect on the outgrowth of 
tubular  structures.  Furthermore,  the  optimal  concentra- 
tions needed to induce mitogenesis and tubular structures 
differ an order of magnitude both for bFGF and VEGF. 
Whether this reflects the involvement of different recep- 
tors for bFGF and VEGF in mitogenesis and the forma- 
tion of tubular structures remains to be investigated. 
The  importance  of  additional  mechanisms  by  which 
bFGF and VEGF may act is stressed by our observation 
that during long-term stimulation of hMVEC with TNFet, 
the presence of growth factors (bFGF or VEGF165)  is nec- 
essary to give an accelerating u-PA production after several 
days of incubation. This unexpected observation may sug- 
gest that the addition of bFGF and/or VEGF165 to hMVEC 
facilitates hMVEC to respond to TNFet with regard to u-PA 
production during continuous exposure to TNFa.  If that 
would  be  the  case,  addition  of u-PA  instead  of TNFa 
would not require addition of bFGF and VEGF165 for the 
induction of tubular structures.  Our data indicate that at 
low concentrations of bFGF and VEGF165 u-PA has a rel- 
atively larger effect than TNFa, but that it does not induce 
tubular structures in the absence of the growth factors. It 
should be noted that at present it is not yet known whether 
the increased u-PA production after prolonged incubation 
in the simultaneous presence of TNFet, bFGF, and VEGF165 
is  the  consequence  of an  increased  number of invading 
hMVEC or the prerequisite for hMVEC  to continue the 
invasion into the fibrin gel. 
The involvement of u-PA activity in the invasion of en- 
dothelial cells into the fibrin matrix draws the attention to 
the  proteolytic  properties  of  the  u-PA/u-PAR  system. 
However, it should be taken into account that disruption 
of cell-matrix interaction is only one side of the coin. Si- 
multaneously, the cell has to create new attachment sites 
by which it "pulls" itself into the fibrin matrix. It is likely 
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tachment sites, e.g., by regulation of integrin expression by 
bFGF  (Enenstein et al., 1992) or TNFc(  (Defilippi  et al., 
1991b).  In  this  context,  the  recent  observation  that the 
u-PAR can act as an adhesion receptor for vitronectin and 
that  u-PA  increases  the  interaction  of  u-PAR  with  vi- 
tronectin are of interest (Wei et al., 1994; Rao et al., 1995). 
Enhancement of the number of occupied u-PA receptors 
not only provides  the  cell  with  an  enhanced  local  pro- 
teolytic capacity but also provides the cell the capacity to 
form  new  attachment  sites  with the extracellular  matrix 
molecules.  This mechanism  may provide  the endothelial 
ceils  with  an enhanced capacity  to migrate  in the fibrin 
matrix.  Vitronectin binds avidly to fibrin and hence may 
improve the suitability of the fibrin meshwork for cell in- 
vasion. 
The data presented here, u-PA--dependent formation of 
capillary-like structures of hMVEC in fibrin matrices, may 
seem to be contrary to the fact that u-PA-deficient mice 
develop a normal embryonic and adult vasculature (Car- 
meliet  and Collen,  1994). To our knowledge,  the forma- 
tion of blood vessels during embryonic development is in- 
dependent  of  the  presence  of  fibrin  and  inflammatory 
mediators,  whereas  angiogenesis  in the adult usually in- 
volves fibrin and inflammatory cells. Furthermore, u-PA- 
deficient mice do have problems with several processes in 
which u-PA is thought to be involved, such as migration of 
smooth muscle cells after vascular injury, which are depen- 
dent on the presence of a temporary fibrin matrix (Carme- 
liet and Collen, 1994). Our model is a reflection of "patho- 
logical"  angiogenesis,  and  is  probably  best  comparable 
with angiogenic recanalization of a fibrin clot or the for- 
mation of new blood vessels in the temporary fibrin matrix 
present at sites of chronic inflammation. When angiogene- 
sis proceeds in a fibrous exudate, the matrix to be invaded 
contains different  types of matrix proteins including col- 
lagens. It is likely that invading endothelial cells then also 
attach  to  other matrix  proteins,  including collagens  and 
that detachment of the cells needed for migration requires 
additional  proteases,  such  as  stromelysin,  collagenases, 
and gelatinases.  It may be of significance that the inflam- 
matory mediator TNFe( induces, in addition to u-PA (van 
Hinsbergh  et  al.,  1990; Niedbala  et al.,  1992),  several  of 
these  matrix  metalloproteinases  in  human  endothelial 
cells (Hanemaaijer et al., 1993). The contribution of these 
matrix-degrading proteinases in the formation of tubular 
structures in fibrin and more complex matrices has still to 
be evaluated. 
In summary,  we  found that in  addition to endothelial 
cell  growth  factors  (VEGF165  and  bFGF),  the  cytokine 
TNFa  or exogenously addition of u-PA is needed to in- 
duce in vitro the formation of capillary-like structures by 
hMVEC. Inhibition studies demonstrated that this induc- 
tion  requires  cell-bound  u-PA  activity.  These  data  may 
provide  insight in the  mechanism  of angiogenesis  as  oc- 
curred in pathological conditions in the adult. 
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